JP2015505541A5 - - Google Patents

Download PDF

Info

Publication number
JP2015505541A5
JP2015505541A5 JP2014553622A JP2014553622A JP2015505541A5 JP 2015505541 A5 JP2015505541 A5 JP 2015505541A5 JP 2014553622 A JP2014553622 A JP 2014553622A JP 2014553622 A JP2014553622 A JP 2014553622A JP 2015505541 A5 JP2015505541 A5 JP 2015505541A5
Authority
JP
Japan
Prior art keywords
nasal
carrier material
powder
inhaled
nose
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014553622A
Other languages
English (en)
Japanese (ja)
Other versions
JP6063482B2 (ja
JP2015505541A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/005358 external-priority patent/WO2013110309A1/en
Publication of JP2015505541A publication Critical patent/JP2015505541A/ja
Publication of JP2015505541A5 publication Critical patent/JP2015505541A5/ja
Application granted granted Critical
Publication of JP6063482B2 publication Critical patent/JP6063482B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014553622A 2012-01-28 2012-12-21 トリアゾロ[4,5−d]ピリミジン誘導体 Expired - Fee Related JP6063482B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12000558.2 2012-01-28
EP12000558 2012-01-28
PCT/EP2012/005358 WO2013110309A1 (en) 2012-01-28 2012-12-21 Triazolo[4,5-d]pyrimidine derivatives

Publications (3)

Publication Number Publication Date
JP2015505541A JP2015505541A (ja) 2015-02-23
JP2015505541A5 true JP2015505541A5 (enExample) 2016-12-15
JP6063482B2 JP6063482B2 (ja) 2017-01-18

Family

ID=47561514

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2014553622A Expired - Fee Related JP6063482B2 (ja) 2012-01-28 2012-12-21 トリアゾロ[4,5−d]ピリミジン誘導体

Country Status (15)

Country Link
US (1) US9409914B2 (enExample)
EP (1) EP2807161B1 (enExample)
JP (1) JP6063482B2 (enExample)
KR (1) KR20140117636A (enExample)
CN (1) CN104066734B (enExample)
AR (1) AR089810A1 (enExample)
AU (1) AU2012367141B2 (enExample)
BR (1) BR112014016884A2 (enExample)
CA (1) CA2862694C (enExample)
ES (1) ES2655264T3 (enExample)
IL (1) IL233808B (enExample)
MX (1) MX2014008864A (enExample)
SG (1) SG11201404234YA (enExample)
WO (1) WO2013110309A1 (enExample)
ZA (1) ZA201406323B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9861635B2 (en) * 2013-05-06 2018-01-09 Merck Patent Gmbh Macrocycles as kinase inhibitors
WO2015038417A1 (en) * 2013-09-10 2015-03-19 Asana Biosciences, Llc Compounds for regulating fak and/or src pathways
AU2016251253B2 (en) * 2015-04-24 2020-07-09 Guangzhou Maxinovel Pharmaceuticals Co., Ltd Condensed-ring pyrimidylamino derivative, preparation method therefor, and intermediate, pharmaceutical composition and applications thereof
MA45940B1 (fr) * 2016-08-10 2024-12-31 Takeda Pharmaceutical Company Limited Composé hétérocyclique
PE20191541A1 (es) 2016-12-22 2019-10-23 Calithera Biosciences Inc Composiciones y metodos para inhibir la accion de la arginasa
KR102328423B1 (ko) * 2018-09-11 2021-11-18 재단법인 대구경북첨단의료산업진흥재단 신규 트리아졸로-피리미딘 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
WO2020070053A1 (en) * 2018-10-01 2020-04-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Use of inhibitors of stress granule formation for targeting the regulation of immune responses
WO2021222147A1 (en) * 2020-04-27 2021-11-04 Hibercell, Inc. Heterocyclic gcn2 modulators
GB202008749D0 (en) 2020-06-09 2020-07-22 Ip2Ipo Innovations Ltd Novel compounds
KR20250122240A (ko) 2024-02-06 2025-08-13 한미약품 주식회사 신규한 함질소 헤테로고리 유도체 및 이의 용도
WO2025179188A1 (en) * 2024-02-22 2025-08-28 Juno Therapeutics, Inc. Pyrazole-based inhibitors of dna-dependent protein kinase and compositions and applications in gene editing
CN120504636B (zh) * 2025-07-22 2025-10-31 江西中医药大学 一种磺胺噻唑-甲氧苄啶药物晶盐及其制备方法和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
BR9707495A (pt) 1996-02-13 1999-07-27 Zeneca Ltd Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
JP4464466B2 (ja) 1996-03-05 2010-05-19 アストラゼネカ・ユーケイ・リミテッド 4―アニリノキナゾリン誘導体
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
JP2004502766A (ja) 2000-07-07 2004-01-29 アンギオジェン・ファーマシューティカルズ・リミテッド 血管損傷剤としてのコルヒノール誘導体
CA2410562A1 (en) 2000-07-07 2002-01-31 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
US7560458B2 (en) 2003-07-16 2009-07-14 Janssen Pharmaceutica, N.V. Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
US20090054358A1 (en) 2004-07-19 2009-02-26 The John Hopkins University Flt3 inhibitors for immune suppression
DE102004051827A1 (de) 2004-10-25 2006-05-04 Hörmann KG Antriebstechnik Armbandsender
WO2006045828A1 (en) * 2004-10-29 2006-05-04 Tibotec Pharmaceuticals Ltd. Hiv inhibiting bicyclic pyrimidine derivatives
US20100160349A1 (en) 2005-01-14 2010-06-24 Christopher John Love Triazolopyrimidine derivatives as glycogen synthase kinase 3 inhibitors
WO2006091737A1 (en) * 2005-02-24 2006-08-31 Kemia, Inc. Modulators of gsk-3 activity
NZ598907A (en) * 2009-10-20 2014-03-28 Cellzome Ltd Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors

Similar Documents

Publication Publication Date Title
JP2014526447A5 (enExample)
JP2013544781A5 (enExample)
JP2014509313A5 (enExample)
JP2015505541A5 (enExample)
JP2013534227A5 (enExample)
JP2013541565A5 (enExample)
BR122021002471B8 (pt) Dispositivo de distribuição de droga nasal
WO2014074797A8 (en) Ultra low density pulmonary powders
EA201590286A1 (ru) Аэрозольное ингаляционное устройство
IN2014DN09377A (enExample)
TN2015000395A1 (en) Respirable agglomerates of porous carrier particles and micronized drug
MY191380A (en) Stabilized fixed dose drug composition having mometasone and olopatadine
JP2014528470A5 (enExample)
CL2013000958A1 (es) Dispositivo atomizador nasal para la administracion de una formulacion farmaceutica a traves de la cavidad nasal en dosis controladas, comprende: un cartucho de aerosol presurizado que a su vez incluye un frasco con una formulacion farmaceutica, el accionador comprende una salida de administracion para el penacho de aerosol, donde el orificio de descarga se encuentra dispuesto de manera de dirigir el penacho de aerosol a traves de la salida de administracion; uso.
TN2012000566A1 (en) Dry powder formulation comprising an antimuscarinic drug
EA201390049A1 (ru) Сухой порошковый препарат, содержащий ингибитор фосфодиэстеразы
WO2013038267A8 (en) Tamper resistant pharmaceutical formulations
EA201591869A1 (ru) Композиция, содержащая для повышения стабильности лекарственной формы по меньшей мере два сухих порошка, получаемых распылительной сушкой
MX373138B (es) Inhalador de polvo seco y método de uso.
EA201700182A1 (ru) Состав для повышения стабильности лекарственного препарата, содержащий по меньшей мере один сухой порошок, полученный распылительной сушкой
EA201590734A8 (ru) Вдыхаемые лекарственные средства
MD20160061A2 (ro) Sistem de livrare a medicamentului compus din particule multiple
CA2991760C (en) DRY INHALATION POWDER FORMULATIONS
WO2011093815A3 (en) Pharmaceutical compositions comprising formoterol and mometasone
HK1215167A1 (zh) 可吸入药用组合物和含有该药用组合物的吸入器装置